Current plan

Explorer

Upgrade

Payment details required

One or more limits reached

Daily profile views

0 / 3

Monthly profile views

0 / 15

Searches (last 30 days)

0 / 10

Watchlist name*

Watchlist must have a valid name.

Description (optional)

0/300

Notifications Settings

Public content (accessible by all Finder users)

Select notifications to recieve

Select all

Email Alerts

Receive notifications via email

Daily

Weekly

Monthly

Never

No Notifications are selected

Would you like to select any notifications?

Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

Name*

Work Email* (please provide your email in the organization)

Position*

Notes

8 Characters, Uppercase letter (A-Z),
Lowercase letter (a-z), Digit (0-9)

Passwords do not match

I agree to receive Informational Emails from Startup Nation Finder as defined in the Privacy Policy and Terms of Use

Already have an account?

Or continue with

The link to share this saved search was copied to your clipboard.
Paste it where you want to share.

HomeStartups Mitoconix Bio financials

Claimed by owner Last Update Sep 16, 2024 Suggest Edits Claim Profile

Claimed by owner

Mitoconix Bio

Therapeutics for Neurodegenerative Diseases

PRESUMED INACTIVE Jul 2019 ceased to operate

Mitoconix Bio

Mitoconix Bio Overview

Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases.

The companys lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction. The drug has demonstrated in vivo efficacy in animal models of Huntingtons disease and Parkinsons disease, and it has shown beneficial activity in patient-derived cells of Huntingtons disease, sporadic and genetic Parkinsons disease, and sporadic and genetic Alzheimers disease.